This inventor holds 29 USPTO granted patents and 2 published patent applications, plus 11 CIPO patents and 14 EPO patents, primarily in Dipeptidyl Peptidase IV Inhibitors. Top assignees: Probiodrug Ag, Prosidion Limited, Osi Pharmaceuticals, Inc.. Active years: 2001-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Haale, DE (2008)
- Haale/Saale, DE (2009)
- Radebeul, DE (2012)
- Halle/Saale, DE (2001 - 2017)
- Halle, DE (2007 - 2022)
Company Filing History:
20 out of 73 
3 out of 16 
2 out of 118 Years Active: 2001-2025
Areas of Expertise:
Title: Torsten Hoffmann: Innovator in Glutaminyl Cyclase Inhibition
Introduction: Torsten Hoffmann, a prominent inventor based in Halle/Saale, Germany, has made significant contributions in the field of pharmaceutical science, particularly in developing inhibitors for glutaminyl cyclase. With a remarkable portfolio of 27 patents, Hoffmann's work showcases his commitment to advancing innovative solutions in medicinal chemistry.
Latest Patents: Among Hoffmann's latest inventions are compounds designed to inhibit glutaminyl cyclase (QC, EC 2.3.2.5). These compounds, represented by the formula (I): A-B-D-E (I), include various pharmacologically acceptable forms, including salts, solvates, and polymorphs. The components of this formula consist of multiple substituents that enhance the efficacy of these compounds in therapeutic applications. In addition, Hoffmann has developed novel pyrrolidine derivatives that also serve as inhibitors of glutaminyl cyclase, further expanding the potential for treatment options in related diseases.
Career Highlights: Throughout his career, Torsten Hoffmann has played key roles in two notable companies: Probiodrug AG and Prosidion Limited. His work within these organizations has propelled research initiatives focused on drug development, ultimately leading to his prolific output of patented innovations.
Collaborations: Hoffmann's collaborations with esteemed colleagues such as Hans-Ulrich Demuth and Ulrich Heiser have further enriched his research endeavors. Working alongside such talented individuals has fostered an environment of creativity and knowledge-sharing, enhancing the innovation process in their projects.
Conclusion: Torsten Hoffmann stands out as an influential inventor whose work in the development of glutaminyl cyclase inhibitors has the potential to impact the pharmaceutical industry significantly. His extensive patent portfolio not only reflects his innovative thinking but also demonstrates the vital contributions he continues to make in the realm of medicinal chemistry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile